Oct 17, 2005
Caliper Life Sciences announced an agreement to acquire NovaScreen Biosciences for $22 million, providing “one-stop-shopping for drug discovery instrumentation, and screening and assay development services,” according to Caliper.
Strand Life Sciences (formerly Strand Genomics), of Bangalore, India, launched an in silico predictive ADME/Tox tool, admetis. “admetis couples prebuilt models with a workflow-based modeling platform,” said Kas Subramanian, Strand’s CSO.
Pharmagene, a British human-tissue-based drug discovery company, has agreed to the terms of a merger with Asterand, a private U.S. company focused on human tissue supply and services. The directors of Pharmagene believe that the merger will create a leading company in human tissue supply and research services.
William Emhiser was appointed CEO of Whatman, following the acquisition of Schleicher & Schuell, a German analytical chemistry supplier, which made Whatman the world’s number 3 provider of separations technology to the life sciences industry.